PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
9781467-1	1998	OBJECTIVES: To determine oxygen metabolism, permeability, and blood flow in isolated joints in response to interleukin 1beta (IL-1beta) and contribution of innervation.	Oxygen	25-31	interleukin-1 beta	Equus caballus	126-134
34944138-0	2021	Age and Body Condition Influence the Post-Prandial Interleukin-1beta Response to a High-Starch Meal in Horses.	Starch	88-94	interleukin-1 beta	Equus caballus	51-68
8578682-7	1995	Dot blot analysis indicated that the expression of IL-1 beta was predominant to that of IL-1 alpha in equine PBMC stimulated with LPS or phorbol myristate acetate.	Tetradecanoylphorbol Acetate	137-162	interleukin-1 beta	Equus caballus	51-60
15727913-6	2005	Insulin had no effect on glucose uptake, but treatment with IGF-I, TGF-beta, IL-1beta and TNF-alpha resulted in a significant increase (>65%) in 2-deoxyglucose uptake compared to control values.	Glucose	25-32	interleukin-1 beta	Equus caballus	77-85
15727913-6	2005	Insulin had no effect on glucose uptake, but treatment with IGF-I, TGF-beta, IL-1beta and TNF-alpha resulted in a significant increase (>65%) in 2-deoxyglucose uptake compared to control values.	Deoxyglucose	148-162	interleukin-1 beta	Equus caballus	77-85
9104557-5	1997	In contrast, chondrocytes treated with LPS or IL-1 beta synthesised nitrite in a dose-related manner.	Nitrites	68-75	interleukin-1 beta	Equus caballus	46-55
34944138-2	2021	Previous research indicated a postprandial elevation in plasma concentrations of interleukin-1beta (IL-1beta), a pro-inflammatory cytokine, after consuming 1.2 g of non-structural carbohydrates/kilogram of body weight.	Carbohydrates	180-193	interleukin-1 beta	Equus caballus	81-98
29034249-14	2017	Interestingly, misoprostol pretreatment enhanced IL-1beta protein synthesis following 6 h of LPS stimulation, while misoprostol posttreatment inhibited IL-1beta protein production after 24 h of LPS stimulation.	Misoprostol	15-26	interleukin-1 beta	Equus caballus	49-57
34448617-7	2021	In horses that received triamcinolone acetonide and hyaluronan, synovial fluid interleukin-1beta, prostaglandin E2, and CTX-II concentrations decreased after treatment, suggesting this treatment inhibited progression of hyaline cartilage degeneration and inflammatory processes.	Triamcinolone Acetonide	24-47	interleukin-1 beta	Equus caballus	79-96
34448617-7	2021	In horses that received triamcinolone acetonide and hyaluronan, synovial fluid interleukin-1beta, prostaglandin E2, and CTX-II concentrations decreased after treatment, suggesting this treatment inhibited progression of hyaline cartilage degeneration and inflammatory processes.	Hyaluronic Acid	52-62	interleukin-1 beta	Equus caballus	79-96
34095281-7	2021	The inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1beta) increased significantly in SF in the highest amikacin dose group, despite the fact that increases in SF cell counts were not observed.	Amikacin	146-154	interleukin-1 beta	Equus caballus	71-89
32093379-2	2020	The effect of orally administered resveratrol on tumor necrosis factor (TNF), interleukin-1beta (IL-1beta), leukocyte phagocytic activity or oxidative burst function have not been reported in horses.	Resveratrol	34-45	interleukin-1 beta	Equus caballus	78-95
29554899-8	2018	Stanozolol treatment reduced gene expression of MMP-13, MMP-1, IL-6 and COX-2 in both normal and IL-1beta treated chondrocytes.	Stanozolol	0-10	interleukin-1 beta	Equus caballus	97-105
29749312-11	2018	IL-1beta mediated suppression of GAG synthesis was not rescued by IL-10.	Glycosaminoglycans	33-36	interleukin-1 beta	Equus caballus	0-8
29249319-11	2018	Finally, the addition of ePL to LPS-stimulated monocytes in the presence of various concentrations of DHS resulted to statistically significant decrease of TNF-alpha and IL-1beta compared to the control groups.	dhs	102-105	interleukin-1 beta	Equus caballus	170-178
31675958-8	2019	Different PL preparations were then applied in cartilage culture with interleukin-1 beta and cultured for 10 days.	pl	10-12	interleukin-1 beta	Equus caballus	70-88
29701083-0	2019	Elevated Glucose Levels Preserve Glucose Uptake, Hyaluronan Production, and Low Glutamate Release Following Interleukin-1beta Stimulation of Differentiated Chondrocytes.	Glucose	9-16	interleukin-1 beta	Equus caballus	108-125
31371681-6	2019	Azithromycin decreased the expression of IL-8 (P=0.03, one-tailed) and IL-1beta (P=0.047, one-tailed) but failed to improve the other variables evaluated.	Azithromycin	0-12	interleukin-1 beta	Equus caballus	71-79
30836143-0	2019	Omega-3 fatty acids and docosahexaenoic acid oxymetabolites modulate the inflammatory response of equine recombinant interleukin1beta-stimulated equine synoviocytes.	Fatty Acids, Omega-3	0-19	interleukin-1 beta	Equus caballus	117-133
30836143-0	2019	Omega-3 fatty acids and docosahexaenoic acid oxymetabolites modulate the inflammatory response of equine recombinant interleukin1beta-stimulated equine synoviocytes.	Docosahexaenoic Acids	24-44	interleukin-1 beta	Equus caballus	117-133
29034249-14	2017	Interestingly, misoprostol pretreatment enhanced IL-1beta protein synthesis following 6 h of LPS stimulation, while misoprostol posttreatment inhibited IL-1beta protein production after 24 h of LPS stimulation.	Misoprostol	116-127	interleukin-1 beta	Equus caballus	152-160
29034249-15	2017	At the mRNA level, misoprostol pre- and posttreatment inhibited LPS-induced TNFalpha, IL-1beta, and IL-6 mRNA production but did not affect IL-8 mRNA.	Misoprostol	19-30	interleukin-1 beta	Equus caballus	86-94
25998424-4	2015	Very low levels of oxygen (<1%), acidosis (pH 6.2), and exposure to IL-1beta led to reductions in cell viability, increased GAG release, alterations in DeltaPsim and ROS levels, and reduced GSH:GSSG ratio.	Glycosaminoglycans	127-130	interleukin-1 beta	Equus caballus	71-79
25998424-4	2015	Very low levels of oxygen (<1%), acidosis (pH 6.2), and exposure to IL-1beta led to reductions in cell viability, increased GAG release, alterations in DeltaPsim and ROS levels, and reduced GSH:GSSG ratio.	Reactive Oxygen Species	169-172	interleukin-1 beta	Equus caballus	71-79
25998424-4	2015	Very low levels of oxygen (<1%), acidosis (pH 6.2), and exposure to IL-1beta led to reductions in cell viability, increased GAG release, alterations in DeltaPsim and ROS levels, and reduced GSH:GSSG ratio.	Glutathione Disulfide	193-196	interleukin-1 beta	Equus caballus	71-79
25998424-4	2015	Very low levels of oxygen (<1%), acidosis (pH 6.2), and exposure to IL-1beta led to reductions in cell viability, increased GAG release, alterations in DeltaPsim and ROS levels, and reduced GSH:GSSG ratio.	Glutathione Disulfide	197-201	interleukin-1 beta	Equus caballus	71-79
22578853-10	2012	LPS and Poly IC induced respectively significant increases of TNF-alpha, IFN-beta, IL-6, IL-1beta, and TNF-alpha, IFN-beta, IP-10 and RANTES, both before and after exercise.	Poly I-C	8-15	interleukin-1 beta	Equus caballus	89-97
24678847-8	2014	Pre-treatment with ASU + EGCG significantly (P < 0.001) decreased gene expression of IL-1beta, TNF-alpha, IL-6, COX-2, and IL-8 in cytokine-activated chondrocytes.	asu	19-22	interleukin-1 beta	Equus caballus	88-96
24555068-2	2013	The aim of this study was to determine whether non-toxic concentrations of curcumin can reduce interleukin-1beta (IL-1beta)-stimulated inflammation and catabolism in an explant model of cartilage inflammation.	Curcumin	75-83	interleukin-1 beta	Equus caballus	114-122
24555068-5	2013	Prostaglandin E 2 (PGE 2) and matrix metalloproteinase (MMP)-3 release into the secretome of IL-1beta-stimulated explants was measured using a competitive ELISA and western blotting respectively.	Dinoprostone	0-17	interleukin-1 beta	Equus caballus	93-101
24555068-5	2013	Prostaglandin E 2 (PGE 2) and matrix metalloproteinase (MMP)-3 release into the secretome of IL-1beta-stimulated explants was measured using a competitive ELISA and western blotting respectively.	Dinoprostone	19-24	interleukin-1 beta	Equus caballus	93-101
24555068-11	2013	Curcumin (>=3muM) significantly reduced IL-1beta-stimulated PG ( p<0.05) and PGE 2 release ( p<0.001) from explants, whilst curcumin (>=12muM) significantly reduced MMP-3 release ( p<0.01).	Curcumin	0-8	interleukin-1 beta	Equus caballus	43-51
25407884-4	2015	Rolipram was the most potent inhibitor of cytokine production (IC50 0.84 and 4.68 mum for TNF-alpha and IL-1beta, respectively) with almost complete inhibition of TNF-alpha, but inhibited IL-1beta by only 39.46%.	Rolipram	0-8	interleukin-1 beta	Equus caballus	104-112
25407884-4	2015	Rolipram was the most potent inhibitor of cytokine production (IC50 0.84 and 4.68 mum for TNF-alpha and IL-1beta, respectively) with almost complete inhibition of TNF-alpha, but inhibited IL-1beta by only 39.46%.	Rolipram	0-8	interleukin-1 beta	Equus caballus	188-196
25407884-5	2015	Azithromycin produced almost complete inhibition of both cytokines, but tended to be less potent than rolipram (IC50 10.66 and 17.4 mum for TNF-alpha and IL-1beta, respectively).	Azithromycin	0-12	interleukin-1 beta	Equus caballus	154-162
25407884-5	2015	Azithromycin produced almost complete inhibition of both cytokines, but tended to be less potent than rolipram (IC50 10.66 and 17.4 mum for TNF-alpha and IL-1beta, respectively).	Rolipram	102-110	interleukin-1 beta	Equus caballus	154-162
25407884-6	2015	Metformin inhibited TNF-alpha production with similar potency to rolipram and azithromycin (IC50 3.35 mum) but showed significantly lower efficacy (45.93%; P < 0.05), and had no inhibitory effect on IL-1beta.	Metformin	0-9	interleukin-1 beta	Equus caballus	202-210
25407884-7	2015	Ethyl pyruvate was the least potent (IC50 68.35 mum and >10 mm for TNF-alpha and IL-1beta production, respectively).	ethyl pyruvate	0-14	interleukin-1 beta	Equus caballus	84-92
24645833-14	2015	RESULTS: Expression of IL1beta mRNA was lower after treatment with dexamethasone (P<0.001) and mycobacterial cell wall extract (P<0.05) when compared with control.	Dexamethasone	67-80	interleukin-1 beta	Equus caballus	23-30
24678847-8	2014	Pre-treatment with ASU + EGCG significantly (P < 0.001) decreased gene expression of IL-1beta, TNF-alpha, IL-6, COX-2, and IL-8 in cytokine-activated chondrocytes.	epigallocatechin gallate	25-29	interleukin-1 beta	Equus caballus	88-96
24678847-10	2014	CONCLUSIONS: We demonstrate that ASU + EGCG inhibits cytokine-induced gene expression of IL-1beta, TNF-alpha, IL-6, COX-2, and IL-8 through modulation of NF-kappaB.	asu	33-36	interleukin-1 beta	Equus caballus	89-97
24678847-10	2014	CONCLUSIONS: We demonstrate that ASU + EGCG inhibits cytokine-induced gene expression of IL-1beta, TNF-alpha, IL-6, COX-2, and IL-8 through modulation of NF-kappaB.	epigallocatechin gallate	39-43	interleukin-1 beta	Equus caballus	89-97
24530239-5	2014	To investigate the hypothesis that IL-1beta is responsible for the increase in the synthesis of PGE2 and in the reduction of 5-LO products, equine whole blood (EWB) was treated with lipopolysaccharide (LPS).	Dinoprostone	96-100	interleukin-1 beta	Equus caballus	35-43
24530239-6	2014	In vitro treatment of EWB with LPS resulted in increased expression of IL-1beta while expression of 5-LO was suppressed.	HLA-B*07 antigen	22-25	interleukin-1 beta	Equus caballus	71-79
24530239-8	2014	Pretreatment of EWB with IL-1beta followed by calcium ionophore A23187 (CI) reduced synthesis of 5-LO products.	HLA-B*07 antigen	16-19	interleukin-1 beta	Equus caballus	25-33
24530239-11	2014	The result of this study indicated that increased PGE2 production led to reduction in 5-LO products in LPS-treated EWB via IL-1beta.	Dinoprostone	50-54	interleukin-1 beta	Equus caballus	123-131
24373218-14	2013	DMMB assays suggested that carprofen initially inhibited IL-1beta-induced GAG release, but this effect was transient.	dimethylmethylene blue	0-4	interleukin-1 beta	Equus caballus	57-65
24373218-14	2013	DMMB assays suggested that carprofen initially inhibited IL-1beta-induced GAG release, but this effect was transient.	carprofen	27-36	interleukin-1 beta	Equus caballus	57-65
24373218-15	2013	Overall, during the two time courses, GAG release was 58.67% +- 10.91% (SD) for IL-1beta versus 52.91% +- 9.35% (SD) with carprofen + IL-1beta.	Glycosaminoglycans	38-41	interleukin-1 beta	Equus caballus	80-88
21430601-11	2011	Foals receiving hydrocortisone had significantly decreased endotoxin-induced expression of TNF-alpha, IL-6, IL-8, and IL-1beta.	Hydrocortisone	16-30	interleukin-1 beta	Equus caballus	118-126
20113225-6	2010	RESULTS: IL-1 beta increased GAG release and aggrecanase activity (11-fold).	Glycosaminoglycans	29-32	interleukin-1 beta	Equus caballus	9-18
21492212-10	2011	There was a significant reduction in TNFalpha, IL-1beta and IL-6 gene expression in endotoxin stimulated whole blood from horses 6 h after receiving 150 mg/kg bwt ethyl pyruvate.	ethyl pyruvate	163-177	interleukin-1 beta	Equus caballus	47-55
21117899-4	2011	In addition, IL-1beta-treated pellets showed decreased safranin O staining and increased COMP immunostaining and MMP-13 concentrations in culture supernatants.	phenosafranine	55-65	interleukin-1 beta	Equus caballus	13-21
19766323-2	2010	In this study, we determined the effects of an adenosine A(2A) receptor agonist, ATL313, on the expression of mRNAs for four pro-inflammatory mediators, IL-1beta, IL-8, COX-2, and TNF-alpha, and the mRNA and protein for the anti-inflammatory cytokine, IL-10 in equine monocytes incubated with lipopolysaccharide (LPS).	ATL 313	81-87	interleukin-1 beta	Equus caballus	153-161
19566470-9	2009	In the other experiment, synovial fluid PGE(2), GAG, and protein concentrations and leukocyte count increased after intra-articular injections of IL-1beta (compared with effects of saline solution injections) in horses that received no DN; NO concentration was not affected.	Prostaglandins E	40-43	interleukin-1 beta	Equus caballus	146-154
19070370-8	2009	However, only SB203580 pretreatment significantly reduced LPS-stimulated IL-1beta and IL-8 mRNA expression and only pretreatment with SB202190 significantly reduced LPS-stimulated TNFalpha and IL-6 mRNA expression.	SB 203580	14-22	interleukin-1 beta	Equus caballus	73-81
19210917-7	2009	After injections of crude equine gonadotropin (CEG; LH effect) or IL-1beta, progesterone and PGF2alpha levels increased, whereas 17beta-oestradiol decreased.	Progesterone	76-88	interleukin-1 beta	Equus caballus	66-74
19210917-13	2009	We demonstrated in vivo that IL-1beta has an effect on steroids and PGF2alpha secretion in the preovulatory follicle.	Steroids	55-63	interleukin-1 beta	Equus caballus	29-37
19210917-13	2009	We demonstrated in vivo that IL-1beta has an effect on steroids and PGF2alpha secretion in the preovulatory follicle.	Dinoprost	68-77	interleukin-1 beta	Equus caballus	29-37
17599753-9	2007	Basal and IL-1beta-induced up-regulation of MMP13 mRNA was blocked by all concentrations of geldanamycin tested.	geldanamycin	92-104	interleukin-1 beta	Equus caballus	10-18
18346142-6	2008	Compared with feed changes alone, dexamethasone administration further reduced the expression of IL-8, CXCL2, and IL-1beta in the BALF cells 3.3-, 2.5-, and 4.7-fold, respectively.	Dexamethasone	34-47	interleukin-1 beta	Equus caballus	114-122
18006077-11	2008	With IL-1beta, the luminol-enhanced CL response of neutrophils was short-lived and inversely proportional to the cytokine concentration: the CL response returned to baseline after 12 min, and became even lower than the baseline value for 10 and 100 ng IL-1beta.	Luminol	19-26	interleukin-1 beta	Equus caballus	5-13
18006077-11	2008	With IL-1beta, the luminol-enhanced CL response of neutrophils was short-lived and inversely proportional to the cytokine concentration: the CL response returned to baseline after 12 min, and became even lower than the baseline value for 10 and 100 ng IL-1beta.	Luminol	19-26	interleukin-1 beta	Equus caballus	252-260
17975975-7	2007	RESULTS: Laminar concentrations of IL-1beta, IL-6, IL-8, COX-2, ICAM-1, and E-selectin mRNA were significantly increased in ETP horses, compared with control horses.	etp	124-127	interleukin-1 beta	Equus caballus	35-43
11763181-1	2001	OBJECTIVE: To evaluate the effects of orally administered phenylbutazone on proteoglycan synthesis and chondrocyte inhibition by IL-1beta in articular cartilage explants of horses.	Phenylbutazone	58-72	interleukin-1 beta	Equus caballus	129-137
16740087-7	2006	RESULTS: IL-1beta-induced GAG loss from cartilage was significantly less in cocultures than in cartilage-only cultures.	Glycosaminoglycans	26-29	interleukin-1 beta	Equus caballus	9-17
16740087-10	2006	CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that synoviocytes secrete 1 or more mediators that preferentially protect matrix GAG metabolism from the degradative effects of IL-1beta.	Glycosaminoglycans	133-136	interleukin-1 beta	Equus caballus	180-188
14525533-1	2003	Interleukin 1 beta (IL-1 beta) inhibits the LH-induced resumption of meiosis of equine oocytes in vitro.	Luteinizing Hormone	44-46	interleukin-1 beta	Equus caballus	20-29
14525533-12	2003	IL-1 beta (50 ng ml(-1)) significantly inhibited the eLH-induced IVM of oocytes (P<0.05) compared with medium 3.	2-(naphthalen-1-yl)-1,3-thiazole-4-carboxylic acid	53-56	interleukin-1 beta	Equus caballus	0-9
12405690-8	2002	At 25 mg/ml glucosamine also prevented IL-1beta-induced increases in nitric oxide production, prostaglandin E2 and proteoglycan release to media.	Glucosamine	12-23	interleukin-1 beta	Equus caballus	39-47
12405690-8	2002	At 25 mg/ml glucosamine also prevented IL-1beta-induced increases in nitric oxide production, prostaglandin E2 and proteoglycan release to media.	Nitric Oxide	69-81	interleukin-1 beta	Equus caballus	39-47
12405690-8	2002	At 25 mg/ml glucosamine also prevented IL-1beta-induced increases in nitric oxide production, prostaglandin E2 and proteoglycan release to media.	Dinoprostone	94-110	interleukin-1 beta	Equus caballus	39-47
11858644-3	2002	Reverse transcriptase polymerase chain reaction methods were used to amplify the entire coding region of the equine IL-1beta mRNA, which was cloned into an expression vector, expressed in E. coli, and purified using a Ni2+ chromatographic method.	Nickel(2+)	218-222	interleukin-1 beta	Equus caballus	116-124
16164745-4	2005	We have hypothesized that equine airway sensitization might induce an oxidative stress and increase the ROS production, which in turn might enhance a production of IL-1beta and airway hyperresponsiveness.	ros	104-107	interleukin-1 beta	Equus caballus	164-172
16164745-9	2005	GSH significantly (p < 0.05) reduced the IL-1beta mRNA expression only in passively sensitized bronchi.	Glutathione	0-3	interleukin-1 beta	Equus caballus	44-52
16164745-13	2005	These effects might be due to an oxidative stress because a pretreatment with GSH decreased the increased IL-1beta mRNA expression and responsiveness to EFS of passively sensitized bronchi.	Glutathione	78-81	interleukin-1 beta	Equus caballus	106-114
15727892-6	2005	RESULTS: IL-1beta and LPS stimulated significant release of GAG, NO, PGE2 and MMP-3.	Glycosaminoglycans	60-63	interleukin-1 beta	Equus caballus	9-17
15727892-6	2005	RESULTS: IL-1beta and LPS stimulated significant release of GAG, NO, PGE2 and MMP-3.	Dinoprostone	69-73	interleukin-1 beta	Equus caballus	9-17
15727892-8	2005	Exposure to ITU also reduced IL-1beta-induced PGE2 release and LPS-induced NO production.	Dinoprostone	46-50	interleukin-1 beta	Equus caballus	29-37
14974582-8	2004	In cartilage explants conditioned with IL1-beta, IGF-II stimulated DNA and GAG synthesis at concentrations of 500 and 50 ng/mL, respectively.	Glycosaminoglycans	75-78	interleukin-1 beta	Equus caballus	39-47
11763181-10	2001	CONCLUSIONS AND CLINICAL RELEVANCE: Oral administration of phenylbutazone for 14 days significantly decreased proteoglycan synthesis in articular culture explants from healthy horses to a degree similar to that induced by in vitro exposure to IL-1beta.	Phenylbutazone	59-73	interleukin-1 beta	Equus caballus	243-251
11067942-6	2000	Before granulocytic death, NF-kappaB activity was suppressed by simultaneous addition of neutralizing anti-IL-1beta and anti-TNF-alpha Abs to the medium of cultured BBSs.	bbss	165-169	interleukin-1 beta	Equus caballus	107-115
10849250-7	2000	Hyaluronan (0.2 microgram/mL) significantly reduced rh-IL-1beta-induced PG release in metacarpal hyaline cartilage (P < 0.01).	Hyaluronic Acid	0-10	interleukin-1 beta	Equus caballus	55-63